CFO Appointment and Director Resignation Announced as Cura Technologies Ltd Releases Quarterly Results
Cura Technologies Limited has announced key changes in its senior management following a Board meeting held on July 30, 2026. The company confirmed the resignation of a Whole-time Director and Chief Financial Officer (CFO) and appointed a new CFO. Additionally, the company released its un-audited financial results for the quarter ended June 30, 2026.The Board meeting approved the unaudited financial results for the quarter ending June 30, 2026, alongside a Limited Review Report for the same period. The board also reviewed and approved the Directors Report for the Financial Year 2025-26 and set the date for the company's 35th Annual General Meeting (AGM).
Leadership Transition and Appointment
Cura Technologies Limited confirmed that Mr. Sangareddypeta Saikiran, who served as a Whole-time Director and Chief Financial Officer (CFO), resigned from his position effective July 30, 2026, citing other professional commitments and personal reasons.Mr. Gundam Vijaya Sarathi Reddy was appointed to fill the role of Chief Financial Officer (CFO) of the company, effective the same date. Mr. Reddy is 49 years old and holds a Bachelor's degree in Commerce. His experience includes over two decades in accounts and finance across organizations in India and overseas, giving him strong expertise in financial management, accounting, and business operations.
The Board meeting concluded at 5:45 p.m. The company further announced that the 35th AGM for the Financial Year 2025-26 is scheduled to be held on Monday, September 28, 2026, at 11:00 a.m. via video conference or other audio visual means (OAVM).
Quarterly Financial Performance Review
The unaudited financial results for the quarter ended June 30, 2026, were disclosed by the company. These results and corresponding financial metrics are available in the provided statement. The company operates exclusively within the IT services segment, meaning segment reporting as per IND AS 108 is not applicable.Key financial figures from the quarterly results (Rs. in Lakhs) are presented below:
| Particulars | Qtr Ended 30-06-2026 Un-Audited | Qtr Ended 31-03-2026 Audited | Qtr Ended 30-06-2025 Un-Audited | FY Ended 31-03-2026 Audited |
|---|---|---|---|---|
| Revenue from Operations (a) | 4.82 | 45.44 | 14.06 | 83.49 |
| Total Income | 4.82 | 45.44 | 14.08 | 83.49 |
| Cost of Programming & AMC Charges (a) | 3.00 | 42.03 | 125 | 43.28 |
| Employee Benefit Expense (c) | 0.54 | 3.10 | 3.15 | 19.65 |
| Finance Cost (d) | 395 | 56.29 | - | 56.29 |
| Total Expenses | 32.60 | 193.28 | 15.01 | 231.94 |
| Profit before tax (b) | 27.78 | -147.84 | 0.93 | -148.45 |
The financial results were prepared in accordance with the recognition and measurement principles laid down in Ind AS prescribed under Section 133 of the Companies Act, 2013. The company's Managing Director certified that the results do not contain any false or misleading statements or omit any material fact.
Stock Price Movement
Dolphin Medical Services Ltd settled at ₹7.48 on Monday, sinking 4.96% as trading concluded. The shares navigated an intraday range that stretched from a low of ₹7.48 up to a high of ₹8.26.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.